Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Marek’s disease and avian influenza vaccine developed
Scientists inserted avian influenza into the turkey herpesvirus that is used in Marek's disease vaccines.

Gene-editing technique faster than previous methods

A vaccine that offers birds protection against Marek’s disease and avian influenza has been developed by scientists at The Pirbright Institute.


Writing in the journal Vaccines, scientists describe how they used a gene-editing technique (CRISPR/Cas9 ) to insert avian influenza into the turkey herpesvirus (HVT) that is used in Marek’s disease vaccines.


The gene codes for haemagglutinin (HA) - an influenza protein that plays a vital role in the virus’ ability to infect host cells and a key target of the host immune response to block infection.


Professor Munir Iqbal, head of the Avian Influenza group at Pirbright, explains: “HVT is already widely used in vaccines against Marek’s disease and can be administered to eggs, enabling automated delivery and providing birds with protection from the day they hatch.

“The additional HA gene we have incorporated will be expressed by HVT when it replicates in host cells, meaning that a single dose of vaccine induces immunity against both viruses."


Compared to previous methods, the new technique is faster, more efficient, and will reduce the time it takes for poultry producers to update vaccine strains. This will enable a quicker response to disease outbreaks and provide better protection.


Prof Iqbal continued: “The genetic engineering process we have developed using CRISPR/Cas9 is far quicker and more efficient than previous technologies, as well as being very consistent and accurate. These attributes are essential for providing fast and reliable vaccine production to protect poultry.


“Improving how we make vaccines is critical for preventing avian influenza outbreaks. Our work could help reduce the spread of disease between birds and reduce the risk of infection for people who work closely with poultry."

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.